This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Nov. 13, 2013


With new study, scientists try to drag drug trials into DNA age
At a Nov. 7 meeting in Washington, D.C., researchers from academia, the Food and Drug Administration, the National Cancer Institute, a leading patient advocacy group, and several drug companies are describing a new clinical trial in lung cancer that could fundamentally change the way cancer drugs are studied and approved, speeding medicines that target specific genetic mutations in cancer toward the market and patients.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Oxygen levels in tumors affect response to treatment
Medical Xpress
The genetic make-up of a patient's tumor could be used to personalize his or her treatment and help decide whether he or she would benefit from receiving additional drugs as part of a radiotherapy program, according to a recent study involving scientists from the Manchester Cancer Research Centre.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Researchers apply new technique to manipulate virus, make it a possible cancer treatment
Medical Xpress
Purdue University researchers successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector. "This virus had been known to be a good vector for delivering therapeutic cargo; however it naturally infected all kinds of cells, and these diversions would compete with what we were instructing it to target," said Richard Kuhn, the Gerald and Edna Mann director of Purdue's Bindley Biosciences Center.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  What You Wish Your Peers Would Share With You.
One hour now will save you three years of anxiety. This webinar will cover topics from Fee for Value to the type of IT capabilities you will need to be successful within the Affordable Care Act.
November 12, 2013
Two convenient times – 11 AM Central and then 11 AM Pacific.
Click here to choose your time and register.

Colorectal cancer tests save lives
Colorectal cancer (CRC) is the second leading cancer killer of men and women in the U.S., following lung cancer. The U.S. Preventive Services Task Force (USPSTF) recommends three CRC screening tests that are effective at saving lives: colonoscopy, stool tests (guaiac fecal occult blood test-FOBT or fecal immunochemical test-FIT), and sigmoidoscopy (now seldom done). Testing saves lives, but only if people get tested. Studies show that people who are able to pick the test they prefer are more likely to actually get the test done. Increasing the use of all recommended colorectal cancer tests can save more lives and is cost-effective.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Accreditation 101: Learning the Basics of CoC Sccreditation and Standards
Are you a new staff member just learning the ropes of CoC-accreditation?
Is your cancer program considering CoC accreditation and you want to learn about the CoC Standards?
Do you need a basic refresher on the CoC accreditation process and standards?

If you answered yes to any of these questions, then plan to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Austin, Texas on Feb. 28, 2014. This is the only program developed and taught by CoC surveyors and staff that reviews the CoC Standards, provides practical information on how to achieve compliance, and discusses the important role you and your cancer team play throughout the continuum of cancer care. Get the information you need from the people involved in standard development and the survey process. For additional information go to

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Tamoxifen resistance in breast cancer patients may have mutated gene to blame
The Plain Dealer
Researchers have discovered a mutated version of the estrogen receptor, the presence of which may explain why the drug tamoxifen (brand names: Novaldex and Soltamox) is no longer effective in some patients being treated for ER-positive breast cancer. The findings were published online Nov. 11 in Cancer Research, a journal of the American Association for Cancer Research.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Oncology OnTrack Supports Nurse Navigation
Oncology OnTrack is used to navigate patients with any cancer type from screening to diagnosis, treatment and survivorship, interfaces with other programs and supports accreditations.
EQUICARE CS - Cancer Navigation and Survivorship

EQUICARE CS provides all three facets of continuum of care services and has included information on their services in the Proprietary Material section of the Best Practices Repository section on the CoC website.

Building a bridge between oncology and physical therapy
Oncology Nurse Advisor
The power of physical therapy to improve the health and well-being of patients who have undergone treatment for cancer is practically undisputed. Cancer treatments take a toll on a patient's body in addition to the effects of the disease itself, so the eradication of cancer is not always the final step in a patient's recovery. Laurie Sweet, a clinical resource analyst at The Johns Hopkins Cancer Rehabilitation Program in East Baltimore describes physical therapy as the Yin to cancer's Yang, just as much a part of a cure for the disease as chemotherapy, radiation, or surgery.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

No advantage with asymptomatic screening for ovarian cancer
Clinical Oncology News
Screening of asymptomatic women for ovarian cancer may cause more harm than good. A recent study determined that screening results in unnecessary surgery and that no advantage to early diagnosis was found. Substantial patient anxiety is associated with false-positive screening results, the authors noted.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Increased use of chemotherapy for gastric cancer has not extended OS
OS rates for patients with metastatic noncardia gastric cancer remained stable in the past two decades despite a considerable increase in the use of chemotherapy for those patients, according to results of a population-based study. The analysis included 4,797 patients enrolled in the Eindhoven Cancer Registry in the Netherlands.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
Looking for similar articles? Search here, keyword GASTRIC CANCER.

The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Nov. 6, 2013
Oct. 30, 2013
Oct. 24, 2013
Oct. 23, 2013

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063